Future of clinical proteomics: could targeted multi-protein panels supplant low-throughput methods?

Recent efforts to optimize instrumentation and sample preparation for MS-based applications have made these LDTs promising contenders for clinical utilization. With focused research to answer quality assessment requirements, data interpretability, method scalability, and ease of use, MS-based LDTs can revolutionize clinical diagnostics. Drawing parallels to other omics technologies, these LDTs can address the long-standing multiplexing hinge and further establish multi-protein diagnostics as next-generation diagnostics of low-throughput methods.